| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871674P | 2013-08-29 | 2013-08-29 | |
| PCT/IB2014/001637WO2015028875A2 (en) | 2013-08-29 | 2014-08-28 | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
| Publication Number | Publication Date |
|---|---|
| MX2016002560Atrue MX2016002560A (en) | 2016-10-26 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002560AMX2016002560A (en) | 2013-08-29 | 2014-08-28 | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir. |
| Country | Link |
|---|---|
| EP (1) | EP3038607A2 (en) |
| AR (1) | AR097512A1 (en) |
| CA (1) | CA2918707A1 (en) |
| HK (1) | HK1220390A1 (en) |
| IL (1) | IL244107A0 (en) |
| MX (1) | MX2016002560A (en) |
| TW (1) | TW201542212A (en) |
| WO (1) | WO2015028875A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201622731A (en)* | 2014-04-08 | 2016-07-01 | 泰瓦藥品工業有限公司 | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising darunavir and ritonavir |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| KR101777564B1 (en) | 2016-05-30 | 2017-09-12 | 영남대학교 산학협력단 | Tablet composition comprising tenofovir disoproxil free base and preparation method thereof |
| WO2018153977A1 (en)* | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| CN108727401A (en)* | 2017-04-20 | 2018-11-02 | 盐城迪赛诺制药有限公司 | Darunavir novel crystal forms and its preparation method and application |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| WO1994004492A1 (en) | 1992-08-25 | 1994-03-03 | G.D. Searle & Co. | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| MY121765A (en) | 1998-07-20 | 2006-02-28 | Abbott Lab | Polymorph of ritonavir |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| HRP20140379A2 (en) | 2003-01-14 | 2014-07-18 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| HRP20080612T3 (en)* | 2004-07-08 | 2009-01-31 | Tibotec Pharmaceuticals Ltd. | COMBINATION TENOFOVIRA, RITONAVIRA I TMC114 |
| AR045841A1 (en)* | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | A SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES THE TIAZOLIL METHYL ESTER OF THE ACID [5S- (5R *, 8R *, 10R *, 11R *)] -10- HYDROXY-2-METHYL-5- (1-METHYTILE) -1- [2 - (1-METHYLE) -4-TIAZOLIL] -3,6-DIOXO-8,11-BIS (PHENYLMETIL) -2,4,7,12- TETRAAZATRIDECAN-13-OICO AND A PROCEDURE TO PREPARE IT. |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (en) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
| US20100183716A1 (en)* | 2007-06-22 | 2010-07-22 | Bristo-Meyers Squibb Company | Tableted compositions containing atazanavir |
| PA8809601A1 (en) | 2007-12-24 | 2009-07-23 | Cipla Ltd | ANTI-RETROVIRAL COMBINATION |
| EP2365798A2 (en)* | 2008-11-21 | 2011-09-21 | Ultimorphix Technologies B.v. | Wet granulation of tenofovir, emtricitabine and efavirenz |
| WO2011013110A1 (en)* | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Unit dosage forms of hiv protease inhibitors |
| EP2332532A1 (en)* | 2009-11-20 | 2011-06-15 | Assistance Publique, Hopitaux De Paris | New multi-therapy administration patterns suitable for treating persons affected by human immunodeficiency virus (HIV) |
| EP2332544A1 (en) | 2009-11-20 | 2011-06-15 | Assistance Publique, Hopitaux De Paris | New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV) |
| LT2729128T (en) | 2011-07-07 | 2016-11-10 | Janssen Sciences Ireland Uc | Darunavir formulations |
| WO2013057469A1 (en) | 2011-10-20 | 2013-04-25 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| GB201118182D0 (en)* | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB201119032D0 (en)* | 2011-11-03 | 2011-12-14 | Isis Innovation | Multisomes: encapsulated droplet networks |
| AU2013204731C1 (en)* | 2012-02-03 | 2017-08-31 | Gilead Sciences, Inc. | Therapeutic compounds |
| US20150045400A1 (en)* | 2012-03-01 | 2015-02-12 | Bandi Parthasaradhi Reddy | Ritonavir compositions |
| WO2014184553A1 (en)* | 2013-05-15 | 2014-11-20 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| Publication number | Publication date |
|---|---|
| EP3038607A2 (en) | 2016-07-06 |
| TW201542212A (en) | 2015-11-16 |
| WO2015028875A3 (en) | 2015-11-19 |
| CA2918707A1 (en) | 2015-03-05 |
| IL244107A0 (en) | 2016-04-21 |
| WO2015028875A8 (en) | 2016-09-01 |
| AR097512A1 (en) | 2016-03-23 |
| HK1220390A1 (en) | 2017-05-05 |
| WO2015028875A2 (en) | 2015-03-05 |
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2021000550A (en) | Tofacitinib oral sustained release dosage forms. | |
| EA201792591A1 (en) | PHARMACEUTICAL PREPARATIONS | |
| IL243786A0 (en) | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir | |
| IL248095A0 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir | |
| PH12016501841A1 (en) | Immunosuppressant formulation | |
| MX2016002560A (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir. | |
| MX2018005358A (en) | Optimised high-dose mesalazine-containing tablet. | |
| MX2016006087A (en) | Rapidly disintegrating formulations and methods of use. | |
| MX368268B (en) | Hiv treatment formulation of atazanavir and cobicistat. | |
| CY1119522T1 (en) | (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| MA40496A (en) | Capsaicinoids and uses thereof as medicaments | |
| MX2018010065A (en) | Oral dosage form comprising rifaximin in form beta. | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| IN2013MU03370A (en) | ||
| PH12017501979A1 (en) | Pharmaceutical compound | |
| IN2013CH05288A (en) | ||
| JO3641B1 (en) | Antiretroviral composition | |
| IN2014DN07895A (en) | ||
| IN2013MU02015A (en) | ||
| EP2968127A4 (en) | Low-glycerin formulations for hiv treatment and prevention | |
| MD4291B1 (en) | Medicinal preparation for the treatment of otitis | |
| PH12017501982A1 (en) | Pharmaceutical compound | |
| HK40029504A (en) | Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv |